

# SNX29 siRNA (h2): sc-93024

## BACKGROUND

SNX29 (sorting nexin-29), also known as RUNDC2A, is an 813 amino acid protein that contains one PX (phox homology) domain and one RUN domain. SNX29 exists as two alternatively spliced isoforms and belongs to the sorting nexin family. The gene that encodes SNX29 consists of more than 522,000 bases and maps to human chromosome 16p.13.13. Encoding over 900 genes and consisting of approximately 90 million base pairs, chromosome 16 makes up nearly 3% of the human genome and is associated with a variety of genetic disorders, such as giant axonal neuropathy, Rubinstein-Taybi syndrome and Crohn's disease. An association with systemic lupus erythematosus and a number of other autoimmune disorders with the pericentromeric region of chromosome 16 has led to the identification of SLC5A11 as a potential autoimmune modifier.

## REFERENCES

1. Mentzer, W.C., et al. 1977. An unusual form of chronic neutropenia in a father and daughter with hypogammaglobulinaemia. *Br. J. Haematol.* 36: 313-322.
2. Baraitser, M. and Preece, M.A. 1983. The Rubinstein-Taybi syndrome: occurrence in two sets of identical twins. *Clin. Genet.* 23: 318-320.
3. Breuning, M.H., et al. 1993. Rubinstein-Taybi syndrome caused by submicroscopic deletions within 16p13.3. *Am. J. Hum. Genet.* 52: 249-254.
4. Bomont, P., et al. 2000. The gene encoding gigaxonin, a new member of the cytoskeletal BTB/kelch repeat family, is mutated in giant axonal neuropathy. *Nat. Genet.* 26: 370-374.
5. Kühlenbäumer, G., et al. 2002. Giant axonal neuropathy (GAN): case report and two novel mutations in the gigaxonin gene. *Neurology* 58: 1273-1276.
6. Cho, J.H. 2004. Advances in the genetics of inflammatory bowel disease. *Curr. Gastroenterol. Rep.* 6: 467-473.
7. Mathew, C.G. and Lewis, C.M. 2004. Genetics of inflammatory bowel disease: progress and prospects. *Hum. Mol. Genet.* 1: R161-R168.
8. Seet, L.F. and Hong, W. 2006. The Phox (PX) domain proteins and membrane traffic. *Biochim. Biophys. Acta* 1761: 878-896.

## CHROMOSOMAL LOCATION

Genetic locus: SNX29 (human) mapping to 16p13.13.

## PRODUCT

SNX29 siRNA (h2) is a pool of 2 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10  $\mu$ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see SNX29 shRNA Plasmid (h2): sc-93024-SH and SNX29 shRNA (h2) Lentiviral Particles: sc-93024-V as alternate gene silencing products.

For independent verification of SNX29 (h2) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-93024A and sc-93024B.

## STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNases and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330  $\mu$ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330  $\mu$ l of RNase-free water makes a 10  $\mu$ M solution in a 10  $\mu$ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

## APPLICATIONS

SNX29 siRNA (h2) is recommended for the inhibition of SNX29 expression in human cells.

## SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10  $\mu$ M in 66  $\mu$ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

## GENE EXPRESSION MONITORING

SNX29 (E-3): sc-514318 is recommended as a control antibody for monitoring of SNX29 gene expression knockdown by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgG $\kappa$  BP-HRP: sc-516102 or m-IgG $\kappa$  BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™ Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use m-IgG $\kappa$  BP-FITC: sc-516140 or m-IgG $\kappa$  BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz® Mounting Medium: sc-24941 or UltraCruz® Hard-set Mounting Medium: sc-359850.

## RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor SNX29 gene expression knockdown using RT-PCR Primer: SNX29 (h2)-PR: sc-93024-PR (20  $\mu$ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

## RESEARCH USE

For research use only, not for use in diagnostic procedures.

## PROTOCOLS

See our web site at [www.scbt.com](http://www.scbt.com) for detailed protocols and support products.